New perspectives in the treatment of HBe
β
Thomas Berg
π
Article
π
2005
π
John Wiley and Sons
π
English
β 141 KB
π 2 views
BACKGROUND: Available treatments for hepatitis B e antigen (HBeAg)-negative chronic hepatitis B are associated with poor sustained responses. As a result, nucleoside and nucleotide analogues are typically continued indefinitely, a strategy associated with the risk of resistance and unknown long-term